Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5794355 | 0.85 | TSHR (0.43) | TSHRMAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL1541726 | 0.82 | TRPA1 (0.40) | TSHRMAPK1ALDH1A1TRPA1HCAR1 | |
| SCHEMBL279180 | 0.79 | CYP3A4 (0.39) | TSHRCYP3A4ALDH1A1HPGDHSD17B10 | |
| SCHEMBL2202986 | 0.78 | ALDH1A1 (0.43) | TSHRMAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL790403 | 0.76 | HSD11B1 (0.40) | TSHRMAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL11058092 | 0.76 | TSHR (0.37) | TSHRMAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL3786889 | 0.74 | TSHR (0.48) | TSHRMAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL10338299 | 0.74 | CD44 (0.50) | TSHRMAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL22660160 | 0.74 | HCAR1 (0.36) | TSHRMAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL5511696 | 0.74 | TSHR (0.48) | TSHRMAPK1CYP3A4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022228449-A1 | PREPARATION METHOD FOR POLYIMIDE RESIN AND THIN FILM THEREOF | 上海瑞暨新材料科技有限公司 | 2022-11-03 | — | — | WO | claimed |
| US-5082971-A | TRIFLUOROMETHYLAMINOBENZENES CONTAINING FLUORINE AND/OR CHLORINE AND THEIR PREPARATION | BAYER AKTIENGESELLSCHAFT (DE) | 1992-01-21 | — | — | US | claimed |
| EP-3958865-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-12403135-B2 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2025-09-02 | — | — | US | disclosed |
| CN-112625028-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118812517-A | Antitumor compounds as UPR agonists and uses thereof | 南京圣和药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-02-20 | — | — | US | disclosed |
| EP-3700904-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3700904-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2023-07-19 | — | — | EP | disclosed |
| CN-115490709-A | KRASG12D inhibitor and application thereof in medicine | 四川海思科制药有限公司 | 2022-12-20 | — | — | CN | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2010057899-A1 | CYCLOALKYL AMINO CARBONYL DERIVATIVES AS BRADYKININ-B1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | WO | disclosed |
| EP-0318704-B1 | 3-CYANO-4-PHENYL-PYRROLE DERIVATIVES | BAYER AG (DE) | 1992-12-02 | — | — | EP | disclosed |
| US-5082971-A | TRIFLUOROMETHYLAMINOBENZENES CONTAINING FLUORINE AND/OR CHLORINE AND THEIR PREPARATION | BAYER AKTIENGESELLSCHAFT (DE) | 1992-01-21 | — | — | US | disclosed |
| US-5015757-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1991-05-14 | — | — | US | disclosed |
| US-4960789-A | FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
| EP-0318704-A2 | 3-Cyano-4-phenyl-pyrrole derivatives | BAYER AG (DE) | 1989-06-07 | — | — | EP | disclosed |
| EP-0315863-A2 | Trifluoromethylamino benzenes containing fluorine, and their preparation | BAYER AG (DE) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403135-B2 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | EGFR, ERBB2, ERBB4 | TSHR 2270/4885MAPK1 212/4885CYP3A4 670/4885 |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN2, PTPN5 | TSHR 1667/4885MAPK1 124/4885CYP3A4 4188/4885 |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN2, PTPN5 | TSHR 1667/4885MAPK1 124/4885CYP3A4 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.